NCT06626919 2026-02-25A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related DiseasesArcellx, Inc.Phase 1 Recruiting30 enrolled
NCT05451212 2025-11-10Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia GravisCabaletta BioPhase 1 Completed7 enrolled